Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical
company developing transformative therapies for the treatment of
brain and nervous system disorders, today announced five upcoming
poster presentations at the 49th Annual Meeting of the Society
for Neuroscience, October 19 – 23, 2019 in Chicago, IL. The
poster presentations will highlight preclinical data from three of
Aptinyx’s clinical-stage product candidates that are in development
for chronic pain, PTSD, and cognitive impairment.
“The range of preclinical data being exhibited
across our three development programs demonstrates the broad
utility of our NMDA receptor modulators in the treatment of a
variety of CNS disorders,” said Cassia Cearley, Ph.D., vice
president of research at Aptinyx. “The data generated through
our robust preclinical work underscore our excitement around the
continued advancement of our pipeline programs and support the
therapeutic potential of each of these product candidates in their
respective indications.”
Presentation Details:
NYX-2925:
Presentation Title: NYX-2925, a
novel NMDA receptor modulator, improves chronic pain and its
affective state in rats with paclitaxel-induced neuropathy (Poster
Number: 476.15)Presenter: Nayereh
Ghoreishi-Haack Poster Presentation: Tuesday,
October 22, 2019, 8:00 AM CT
Presentation Title: The novel
NMDA receptor modulator, NYX-2925, enhances NMDAR-mediated current
and LTP, induces changes in cell intrinsic properties, and alters
firing properties in layer 5 pyramidal neurons of rat mPFC
(Poster Number: 748.17)Presenter:
Crystle Kelly, Ph.D. Poster
Presentation: Wednesday, October 23, 2019, 1:00 PM
CT
NYX-783:
Presentation Title: NYX-783, a
novel NMDAR modulator, rescues the detrimental effects of
encephalitis-causing anti-NMDAR antibodies on GluN2B-NMDAR
expression in vitro
(Poster Number: 118.15)Presenter: Mary
Schmidt Poster Presentation: Sunday, October
20, 2019, 8:00 AM CT
NYX-458:Presentation
Title: NYX-458, a novel NMDA receptor modulator, improves
age-related, hippocampal-dependent learning impairment and reverses
changes in plasticity, spine morphology, and protein expression in
rat hippocampus
(Poster Number: 286.04)Presenter: Tegh
Matharu Poster Presentation: Monday, October
21, 2019, 8:00 AM CT
Presentation Title: NMDA
receptor modulation with NYX-458 rescues cognitive impairment and
peripheral growth hormone levels in a clinically relevant rat model
of repeat concussion
(Poster Number: 570.13)Presenter: Luisa
Cacheaux, Ph.D. Poster Presentation: Tuesday,
October 22, 2019, 1:00 PM CT
Oral Presentation on Electrophysiology
in Drug Development:
Presentation Title:
Medium-throughput screening of a proprietary platform of small
molecule, NMDA receptor-modulating compounds in a long-term
potentiation assay using a custom, 4-channel extracellular
recording setupPresenter: Crystle Kelly, Ph.D.
Presentation Time: Sunday, October 20, 2019,
6:45 PM CT
About NYX-2925NYX-2925 is a
novel oral NMDA receptor modulator currently in Phase 2 clinical
development for the treatment of chronic pain. In clinical studies,
NYX-2925 has been shown to have activity that affects central pain
processing, resulting in alleviation of pain and other symptoms
associated with chronic pain conditions. In preclinical models of
numerous neuropathic pain conditions, NYX-2925 has shown robust
activity with a favorable tolerability profile. In Phase 1 and
Phase 2 clinical studies, NYX-2925 has exhibited a favorable safety
and tolerability profile across a wide dose range. The U.S. Food
and Drug Administration has granted Fast Track designation to
Aptinyx’s development of NYX-2925 for the treatment of neuropathic
pain associated with DPN.
About NYX-783 NYX-783 is a
novel, oral NMDA receptor modulator currently in Phase 2
development for the treatment of post-traumatic stress disorder
(PTSD). In preclinical studies of NYX-783, particularly strong
results were observed in psychiatric models, models of fear
extinction, and models of substance abuse. In a Phase 1 clinical
study of NYX-783, ample central nervous system exposure was
observed and the product candidate demonstrated a favorable safety
and tolerability profile, with no serious adverse effects, across a
wide dose range. The U.S. Food and Drug
Administration has granted Fast Track designation to the
development of NYX-783 for the treatment of PTSD.
About NYX-458 NYX-458 is a
novel oral NMDA receptor modulator currently in clinical
development for the treatment of cognitive impairment associated
with Parkinson’s disease. NYX-458 has been shown to reverse
cognitive deficits in non-human primates in a model that is highly
translatable to Parkinson’s disease in humans. Additionally,
NYX-458 has been shown to improve cognitive performance across
various models of neurodegeneration. In a Phase 1 clinical study,
NYX-458 exhibited a favorable safety and tolerability profile
across a wide dose range and achieved CNS exposure in line with
exposure observed with efficacious preclinical dose levels.
About Aptinyx Aptinyx
Inc. is a clinical-stage biopharmaceutical company focused on
the discovery, development, and commercialization of proprietary
synthetic small molecules for the treatment of brain and nervous
system disorders. Aptinyx has a platform for discovery of
novel compounds that work through a unique mechanism to modulate –
rather than block or over-activate – NMDA receptors and enhance
synaptic plasticity, the foundation of neural cell communication.
The company has three product candidates in clinical development in
central nervous system indications, including chronic pain,
post-traumatic stress disorder, and cognitive impairment associated
with Parkinson’s disease. Aptinyx is also advancing
additional compounds from its proprietary discovery platform, which
continues to generate a rich and diverse pipeline of small-molecule
NMDA receptor modulators with the potential to treat an array of
neurologic disorders. For more information,
visit www.aptinyx.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that
are not historical facts are “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding
the company’s business plans and objectives, therapeutic effects of
the company’s product candidates, expectations regarding the
design, implementation, timing, and success of its current and
planned clinical studies, and expectations regarding its uses and
sufficiency of capital. Risks that contribute to the uncertain
nature of the forward-looking statements include: the success,
cost, and timing of the company’s product candidate development
activities and planned clinical studies; the company’s ability to
execute on its strategy; positive results from a clinical study may
not necessarily be predictive of the results of future or ongoing
clinical studies; regulatory developments in the United States and
foreign countries; as well as those risks and uncertainties set
forth in the company’s most recent Annual Report on Form 10-K and
subsequent filings with the Securities and Exchange Commission. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. Aptinyx undertakes no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were
made.
Investor Contacts:Nick
SmithAptinyx Inc.ir@aptinyx.com847-871-0377
Source: Aptinyx Inc.
Aptinyx (NASDAQ:APTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aptinyx (NASDAQ:APTX)
Historical Stock Chart
From Sep 2023 to Sep 2024